Drugs /

brilanestrant

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, SERD ARN-810 binds to the estrogen receptor and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells.

Clinical Trials

View Clinical Trials for brilanestrant

Brilanestrant has been investigated in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials investigating brilanestrant, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (0 open).

ER Positive, HER2 Deficient Expression, and HER2 Negative are the most frequent biomarker inclusion criteria for brilanestrant clinical trials.

Breast carcinoma is the most common disease being investigated in brilanestrant clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Brilanestrant
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating brilanestrant and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,931 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
serd arn-810, rg6046, arn-810, selective estrogen receptor degrader arn-810, ro7056118, gdc-0810
Drug Categories [2]:
Selective estrogen receptor degraders (SERDs)
NCIT ID [1]:
C106235

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.